The results provide novel insight into the neuroprotective mechanisms linked to the activation of cerebral PPARγ and the rationale for conducting additional clinical trials investigating the use of pioglitazone in acute treatment of patients suffering from ischemic stroke [30]. This evidence concerns the gene PPARG and ischemic stroke.